MULTAQ Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Multaq, and what generic alternatives are available?
Multaq is a drug marketed by Sanofi Aventis Us and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-seven patent family members in twenty-eight countries.
The generic ingredient in MULTAQ is dronedarone hydrochloride. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dronedarone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Multaq
A generic version of MULTAQ was approved as dronedarone hydrochloride by LUPIN on January 31st, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MULTAQ?
- What are the global sales for MULTAQ?
- What is Average Wholesale Price for MULTAQ?
Summary for MULTAQ
| International Patents: | 57 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 80 |
| Clinical Trials: | 6 |
| Patent Applications: | 1,168 |
| Drug Prices: | Drug price information for MULTAQ |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MULTAQ |
| What excipients (inactive ingredients) are in MULTAQ? | MULTAQ excipients list |
| DailyMed Link: | MULTAQ at DailyMed |
Recent Clinical Trials for MULTAQ
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| American Heart Association | Phase 4 |
| Duke Clinical Research Institute | Phase 4 |
| University of Utah | Phase 3 |
Pharmacology for MULTAQ
| Drug Class | Antiarrhythmic |
| Mechanism of Action | Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A Inhibitors P-Glycoprotein Inhibitors |
Paragraph IV (Patent) Challenges for MULTAQ
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| MULTAQ | Tablets | dronedarone hydrochloride | 400 mg | 022425 | 7 | 2013-07-01 |
US Patents and Regulatory Information for MULTAQ
MULTAQ is protected by five US patents.
Patents protecting MULTAQ
Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RHYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF
Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | MULTAQ | dronedarone hydrochloride | TABLET;ORAL | 022425-001 | Jul 1, 2009 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sanofi Aventis Us | MULTAQ | dronedarone hydrochloride | TABLET;ORAL | 022425-001 | Jul 1, 2009 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sanofi Aventis Us | MULTAQ | dronedarone hydrochloride | TABLET;ORAL | 022425-001 | Jul 1, 2009 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MULTAQ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | MULTAQ | dronedarone hydrochloride | TABLET;ORAL | 022425-001 | Jul 1, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi Aventis Us | MULTAQ | dronedarone hydrochloride | TABLET;ORAL | 022425-001 | Jul 1, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Sanofi Aventis Us | MULTAQ | dronedarone hydrochloride | TABLET;ORAL | 022425-001 | Jul 1, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MULTAQ
When does loss-of-exclusivity occur for MULTAQ?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 2950
Patent: USO DE DRONEDARONA PARA LA PREPARACION DE UN MEDICAMENTO PARA USO EN LA PREVENCION DE LA HOSPITALIZACION CARDIOVASCULAR O DE LA MORTALIDAD, COMPOSICION FARMACEUTICA, ARTICULO DE FABRICACION Y ENVASE
Estimated Expiration: ⤷ Sign Up
Patent: 2951
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE ESTA, PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 09252897
Patent: Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Estimated Expiration: ⤷ Sign Up
Patent: 09252898
Patent: Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0910631
Patent: uso de dronedarona para a preparação de um medicamento para uso na prevenção de hospitalização cardiovascular ou de mortalidade
Estimated Expiration: ⤷ Sign Up
Patent: 0911198
Patent: uso de dronedarona ou um sal farmaceutimente aceitável da mesma para a preparação de um medicamento para reguular o nível de potássio no sangue
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 21489
Patent: UTILISATION DE DRONEDARONE DANS UN MEDICAMENT UTILISE POUR PREVENIR UN EPISODE CARDIOVASCULAIRE MENANT A L'HOSPITALISATION OU A LA MORT (USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY)
Estimated Expiration: ⤷ Sign Up
Patent: 21491
Patent: UTILISATION DE LA DRONEDARONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI, POUR LA PREPARATION D'UN MEDICAMENT PERMETTANT LA REGULATION DU NIVEAU DE POTASSIUM DANS LE SANG (USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM LEVEL IN THE BLOOD)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 09000919
Patent: Uso de dronedarona o una sal farmaceuticamente aceptable para preparar un medicamento util en la prevencion y/o tratamiento de la hipocalemia.
Estimated Expiration: ⤷ Sign Up
Patent: 09000920
Patent: Uso de dronedarona o una sal farmaceuticamente aceptable para preparar un medicamento util para la prevencion de hospitalizaciones cardiovasculares.
Estimated Expiration: ⤷ Sign Up
China
Patent: 2065855
Patent: Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Estimated Expiration: ⤷ Sign Up
Patent: 2065857
Patent: Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in regulating the potassium level in the blood
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 60064
Patent: USO DE DRONEDARONA PARA LA PREPARACION DE UN MEDICAMENTO PARA USO EN LA PREVENCION DE LA HOSPITALIZACION CARDIOVASCULAR O DE LA MORTALIDAD
Estimated Expiration: ⤷ Sign Up
Patent: 60065
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE ESTA PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 721
Patent: USO DE DRONEDARONA PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA USO EN LA PREVENCIÓN DE LA HOSPITALIZACIÓN CARDIOVASCULAR O DE LA MORTALIDAD
Estimated Expiration: ⤷ Sign Up
Patent: 734
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE ESTA, PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE
Estimated Expiration: ⤷ Sign Up
Dominican Republic
Patent: 010000299
Patent: USO DE DRONEDARONA PARA LA PREPARACION DE UN MEDICAMENTO PARA USO EN LA PREVENCION DE LA HOSPITALIZACION CARDIOVASCULAR O DE LA MORTALIDAD
Estimated Expiration: ⤷ Sign Up
Patent: 010000300
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE ESTA, PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 10010540
Patent: USO DE DRONEDARONA PARA LA PREPARACION DE UN MEDICAMENTO PARA USO EN LA PREVENCION DE LA HOSPITALIZACION CARDIOVASCULAR O DE LA MORTALIDAD
Estimated Expiration: ⤷ Sign Up
Patent: 10010553
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE ESTA, PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE
Estimated Expiration: ⤷ Sign Up
El Salvador
Patent: 10003700
Patent: USO DE DRONEDARONA PARA LA PREPARACION DE UN MEDICAMENTO PARA USO EN LA PREVENCION DE LA HOSPITALIZACION CARDIOVASCULAR O DE LA MORTALIDAD
Estimated Expiration: ⤷ Sign Up
Patent: 10003701
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE ESTA, PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 5017
Patent: СПОСОБ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ИСТОРИЕЙ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ ИЛИ ТРЕПЕТАНИЯ ПРЕДСЕРДИЙ, ИЛИ СУЩЕСТВУЮЩИМИ ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ ИЛИ ТРЕПЕТАНИЕМ ПРЕДСЕРДИЙ, ПРЕДОТВРАЩАЮЩИЙ ГОСПИТАЛИЗАЦИЮ В КАРДИОЛОГИЧЕСКОЕ ОТДЕЛЕНИЕ (METHOD OF TREATING PATIENTS WITH A HISTORY OF ATRIAL FIBRILLATION OR ATRIAL FLUTTER, OR CURRENT ATRIAL FIBRILLATION OR ATRIAL FLUTTER, PREVENTING CARDIOVASCULAR HOSPITALIZATION)
Estimated Expiration: ⤷ Sign Up
Patent: 1071204
Patent: ПРИМЕНЕНИЕ ДРОНЕДАРОНА ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА ДЛЯ ПРИМЕНЕНИЯ В ПРЕДОТВРАЩЕНИИ ГОСПИТАЛИЗАЦИИ В КАРДИОЛОГИЧЕСКОЕ ОТДЕЛЕНИЕ ИЛИ СМЕРТНОСТИ
Estimated Expiration: ⤷ Sign Up
Patent: 1071209
Patent: ПРИМЕНЕНИЕ ДРОНЕДАРОНА ИЛИ ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ДЛЯ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА ДЛЯ РЕГУЛЯЦИИ УРОВНЯ КАЛИЯ В КРОВИ
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 80701
Patent: UTILISATION DE DRONÉDARONE DANS UN MÉDICAMENT UTILISÉ POUR PRÉVENIR UN ÉPISODE CARDIOVASCULAIRE MENANT À L HOSPITALISATION OU À LA MORT (USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY)
Estimated Expiration: ⤷ Sign Up
Patent: 80702
Patent: UTILISATION DE LA DRONÉDARONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI, POUR LA PRÉPARATION D UN MÉDICAMENT PERMETTANT LA RÉGULATION DU NIVEAU DE POTASSIUM DANS LE SANG (USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM LEVEL IN THE BLOOD)
Estimated Expiration: ⤷ Sign Up
Patent: 84564
Patent: Utilisation de dronédarone dans un médicament utilisé pour prévenir un épisode cardiovasculaire menant à l’hospitalisation ou prévenir la fibrillation auriculaire (Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation)
Estimated Expiration: ⤷ Sign Up
Patent: 95862
Patent: UTILISATION DE LA DRONEDARONE DANS LA PREPARATION D'UN MEDICAMENT UTILISE POUR PREVENIR UN EPISODE CARDIOVASCULAIRE MENANT A L'HOSPITALISATION OU PREVENIR LA FIBRILLATION AURICULAIRE (USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR IN THE PREVENTION OF ATRIAL FIBRILLATION)
Estimated Expiration: ⤷ Sign Up
France
Patent: 30148
Patent: UTILISATION DE LA DRONEDARONE POUR LA PREPARATION D'UN MEDICAMENT DESTINE A LA PREVENTION DE L'HOSPITALISATION CARDIOVASCULAIRE OU DE LA MORTALITE (Use of dronedarone to prepare medicament to prevent mortality and/or cardiovascular hospitalizations in patients having e.g. history of atrial fibrillation/atrial flutter, cerebrovascular accident and non-rheumatic valvular heart disease)
Estimated Expiration: ⤷ Sign Up
Patent: 30150
Patent: UTILISATION DE LA DRONEDARONE POUR LA PREPARATION D'UN MEDICAMENT DESTINE A REGULER LE TAUX DE POTASSIUM DANS LE SANG
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 11518147
Estimated Expiration: ⤷ Sign Up
Patent: 11518785
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 3608
Patent: USE OF DRONEDARONE FOR THE PREPARATION OF MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 10011400
Patent: USO DE DRONEDARONA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LO MISMO, PARA LA PREPARACION DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE. (USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM LEVEL IN THE BLOOD.)
Estimated Expiration: ⤷ Sign Up
Patent: 10011414
Patent: USO DE DRONEDARONA PARA LA PREPARACION DE UN MEDICAMENTO PARA USO EN LA PREVENCION DE LA HOSPITALIZACION CARDIOVASCULAR O DE LA MORTALIDAD. (USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY.)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 354
Patent: استخدام الدرونيدارون في دواء يستخدم لمنع اضطرابات القلب والأوعية الدموية التي قد تؤدي إلى دخول المستشفى أو الوفاة
Estimated Expiration: ⤷ Sign Up
Patent: 356
Patent: استخدام الدرونيدارون أو ملح مقبول صيدليا ، لإعداد دواء لتنظيم مستوى البوتاسيوم في الدم
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 8623
Patent: Use of a medicament containing dronedarone with food for preventing cardiovascular hospitalization
Estimated Expiration: ⤷ Sign Up
Nicaragua
Patent: 1000172
Patent: USO DE DRONEDARONA PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA USO EN LA PREVENCIÓN DE LA HOSPITALIZACIÓN CARDIOVASCULAR O DE LA MORTALIDAD.
Estimated Expiration: ⤷ Sign Up
Patent: 1000173
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACÉUTICAMENTE DE ÉSTA, PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE.
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 091777
Patent: DRONEDARONA O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE LA MISMA
Estimated Expiration: ⤷ Sign Up
Patent: 091809
Patent: USO DE DRONEDARONA PARA LA PREPARACION DE UN MEDICAMENTO PARA USO EN LA PREVENCION DE LA HOSPITALIZACION CARDIOVASCULAR O DE LA MORTALIDAD
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1007248
Patent: USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY
Estimated Expiration: ⤷ Sign Up
Patent: 1007391
Patent: USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM IN THE BLOOD
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 100135814
Patent: USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASSIUM LEVEL IN THE BLOOD
Estimated Expiration: ⤷ Sign Up
Patent: 100135909
Patent: USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 19298
Estimated Expiration: ⤷ Sign Up
Patent: 0946108
Patent: Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
Estimated Expiration: ⤷ Sign Up
Patent: 0948354
Patent: Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Estimated Expiration: ⤷ Sign Up
Patent: 1529068
Patent: Use of DRONEDARONE for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 10000454
Patent: USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALISATION OR OF MORTATILY
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 8980
Patent: ЗАСТОСУВАННЯ ДРОНЕДАРОНУ ДЛЯ ПРОФІЛАКТИКИ СЕРЦЕВО-СУДИННИХ ГОСПІТАЛІЗАЦІЙ (USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY)
Estimated Expiration: ⤷ Sign Up
Uruguay
Patent: 767
Patent: USO DE DRONEDARONA PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA USO EN LA PREVENCIÓN DE LA HOSPITALIZACIÓN CARDIOVASCULAR O DE LA MORTALIDAD
Estimated Expiration: ⤷ Sign Up
Patent: 768
Patent: USO DE DRONEDARONA O UNA SAL ACEPTABLE FARMACÉUTICAMENTE DE ÉSTA, PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA REGULAR EL NIVEL DE POTASIO EN LA SANGRE
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering MULTAQ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 072950 | USO DE DRONEDARONA PARA LA PREPARACION DE UN MEDICAMENTO PARA USO EN LA PREVENCION DE LA HOSPITALIZACION CARDIOVASCULAR O DE LA MORTALIDAD, COMPOSICION FARMACEUTICA, ARTICULO DE FABRICACION Y ENVASE | ⤷ Sign Up |
| Taiwan | 548108 | ⤷ Sign Up | |
| New Zealand | 588623 | Use of a medicament containing dronedarone with food for preventing cardiovascular hospitalization | ⤷ Sign Up |
| Austria | 264677 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MULTAQ
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1007030 | 2010008 | Ireland | ⤷ Sign Up | THE CORRECT SPC EXTENSION DATE IS 20230618 (NOT 20230616); PRODUCT NAME: DRONEDARONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/09/591/001-004 20091126 |
| 1007030 | SPC/GB10/029 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DRONEDARONE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/09/591/001 20091126; UK EU/1/09/591/002 20091126; UK EU/1/09/591/003 20091126; UK EU/1/09/591/004 20091126 |
| 1007030 | 384 | Finland | ⤷ Sign Up | |
| 1007030 | 122010000029 | Germany | ⤷ Sign Up | PRODUCT NAME: DRONEDARON ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE DAS HYDROCHLORIDSALZ; REGISTRATION NO/DATE: EU/1/09/591/001-004 20091126 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
